Chimeric Therapeutics Receives US FDA Fast Track Designation for CHM CDH17 CAR-T Therapy

MT Newswires Live

Jun 05, 2025

Chimeric Therapeutics (ASX:CHM) said that the US Food and Drug Administration (FDA) granted fast-track designation to its CHM CDH17 chimeric antigen receptor T-cell (CAR-T) therapy for treating advanced gastroenteropancreatic neuroendocrine tumors in patients who have progressed after prior treatment, according to a Wednesday filing with the Australian bourse.

Fast-track designation aims to expedite the development and review of treatments for serious conditions with unmet needs, providing increased interaction with the US FDA and potential eligibility for a priority review and a rolling biologics license application review, the filing said.

CHM CDH17 is currently in a trial phase assessing safety and efficacy in advanced colorectal, gastric, and intestinal neuroendocrine cancers, the filing added.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2541434820"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2541434820\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2541434820?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-06-05 14:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2541434820","market":"fut","top_or_hot":-1,"title":"Chimeric Therapeutics Receives US FDA Fast Track Designation for CHM CDH17 CAR-T Therapy","media":"MT Newswires Live","content":"<html><body><p> Chimeric <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (ASX:CHM) said that the US Food and Drug Administration (FDA) granted fast-track designation to its CHM CDH17 chimeric antigen receptor T-cell (CAR-T) therapy for treating advanced gastroenteropancreatic neuroendocrine tumors in patients who have progressed after prior treatment, according to a Wednesday filing with the Australian bourse.</p><p>Fast-track designation aims to expedite the development and review of treatments for serious conditions with unmet needs, providing increased interaction with the US FDA and potential eligibility for a priority review and a rolling biologics license application review, the filing said.</p><p>CHM CDH17 is currently in a trial phase assessing safety and efficacy in advanced colorectal, gastric, and intestinal neuroendocrine cancers, the filing added.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Chimeric Therapeutics Receives US FDA Fast Track Designation for CHM CDH17 CAR-T Therapy</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nChimeric Therapeutics Receives US FDA Fast Track Designation for CHM CDH17 CAR-T Therapy\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-06-05 14:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Chimeric <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (ASX:CHM) said that the US Food and Drug Administration (FDA) granted fast-track designation to its CHM CDH17 chimeric antigen receptor T-cell (CAR-T) therapy for treating advanced gastroenteropancreatic neuroendocrine tumors in patients who have progressed after prior treatment, according to a Wednesday filing with the Australian bourse.</p><p>Fast-track designation aims to expedite the development and review of treatments for serious conditions with unmet needs, providing increased interaction with the US FDA and potential eligibility for a priority review and a rolling biologics license application review, the filing said.</p><p>CHM CDH17 is currently in a trial phase assessing safety and efficacy in advanced colorectal, gastric, and intestinal neuroendocrine cancers, the filing added.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"FAST","symbol_name":"快扣","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2541434820","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2541434820","pubTimestamp":1749103219,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Chimeric Therapeutics (ASX:CHM) said that the US Food and Drug Administration (FDA) granted fast-track designation to its CHM CDH17 chimeric antigen receptor T-cell (CAR-T) therapy for treating advanc","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"FAST":"快扣","BK4230":"旅客陆运","CAR":"安飞士","IE00B5TLWC47.USD":"BNY MELLON LONG-TERM GLOBAL EQUITY \"B\" (USD) ACC","BK4585":"ETF&股票定投概念","LENZ":"Therapeutics","BK4139":"生物科技","BK4567":"ESG概念","BK7067":"生物科技","BK4104":"贸易公司与经销商","IE00BFXG0V08.USD":"BNY MELLON GLOBAL LEADERS \"B\" (USD) ACC","BK4588":"碎股","BK4007":"制药","CHM.AU":"CHIMERIC THERAPEUTICS LTD","IE00BYQQ9H92.USD":"BNY MELLON GLOBAL LEADERS \"A\" (USD) ACC","BK4022":"陆运","BK4539":"次新股"},"translate_title":"Chimeric Therapeutics获得美国FDA CHM CDH17 CAR-T疗法快速通道指定","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CHM.AU":0.9,"FAST":1,"CAR":1,"LENZ":1},"content_text":"Chimeric Therapeutics (ASX:CHM) said that the US Food and Drug Administration (FDA) granted fast-track designation to its CHM CDH17 chimeric antigen receptor T-cell (CAR-T) therapy for treating advanced gastroenteropancreatic neuroendocrine tumors in patients who have progressed after prior treatment, according to a Wednesday filing with the Australian bourse.Fast-track designation aims to expedite the development and review of treatments for serious conditions with unmet needs, providing increased interaction with the US FDA and potential eligibility for a priority review and a rolling biologics license application review, the filing said.CHM CDH17 is currently in a trial phase assessing safety and efficacy in advanced colorectal, gastric, and intestinal neuroendocrine cancers, the filing added.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}